Lenzilumab, CAS 1229575-09-0

Product Description: Lenzilumab (KB 003) is a human monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies[1][2].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Rosalie M Sterner, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019 Feb 14;133(7):697-709./[2]Zelalem Temesgen, et al. GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study. Mayo Clin Proc. 2020 Nov;95(11):2382-2394.

CAS Number: 1229575-09-0

Molecular Weight: N/A

Compound Purity: 99.64

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: SARS-CoV

• Artikelnummer: MEXHY-P99207-10
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99207-10
• Green Labware: Nein
• Verpackungseinheit: 10 mg
• Mengeneinheit: STK